The company, founded in 2000 and based in Heidelberg, uses proprietary technology called Kinobeads™ to screen and profile kinases in relevant cells and tissues. This technology helps CellZome identify a new generation of kinase-targeted drugs to treat inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma. The company's pipeline of small-molecule therapeutics includes inhibitors targeting key inflammatory mediators in immune receptor signaling and chemotaxis, such as PI3Kγ and Zap-70.